论文部分内容阅读
对３０例ＡＦＰ阴性原发性肝癌（ＰＨＣ）伴腹水患者用放射免疫分析（ＲＩＡ）进行血清及腹水ＣＥＡ、ＣＡ５０含量联合检测，并与２６例ＡＦＰ阳性ＰＨＣ伴腹水患者、３５例肝硬化腹水患者的血清及腹水ＣＥＡ、ＣＡ５０含量作比较。结果显示：ＡＦＰ阴性ＰＨＣ组血清及腹水ＣＥＡ含量平均值均显著增高，阳性率７３．３％，而ＡＦＰ阳性组的阳性率为３０．８％，两组ＣＥＡ含量比较Ｐ＜０．０１，两组ＣＡ５０含量比较无显著性差异（Ｐ＞０．０５）；但两组与肝硬化腹水组对比则呈非常显著与显著性差异（对于ＣＥＡ，Ｐ＜０．００１－０．０１；对于ＣＡ５０，Ｐ＜０．０５））。结果提示：对ＰＨＣ患者特别是ＡＦＰ阴性者进行ＡＦＰ、ＣＥＡ、ＣＡ５０联合检测有临床实用价值。
A total of 30 cases of AFP-negative primary liver cancer (PHC) with ascites were examined by radioimmunoassay (RIA) for CEA and CA50 levels in serum and ascites, 26 patients with AFP-positive PHC with ascites, and 35 patients with ascites with cirrhosis. Serum and ascites CEA, CA50 content for comparison. The results showed that the average levels of CEA in serum and ascites in AFP-negative PHC group were significantly higher, the positive rate was 73.3%, while the positive rate in AFP-positive group was 30.8%. The CEA content in the two groups was P<0.01. There was no significant difference in the content of CA50 between the two groups (P>0.05), but there was a significant difference between the two groups and the cirrhosis ascites group (for CEA, P<0.001-0.01; for CA50, P<0.05)). The results suggest that the combination of AFP, CEA, and CA50 in patients with PHC, especially AFP negative, has clinical value.